Drotrecogin alpha

LE WE PMID CA

Drotrecogin alpha

725

Drotrecogin alpha

2003 1	Role of activated protein C in the pathophysiology of severe sepsis. [14619357] Am J Crit Care 12(6): 518-24; quiz 525-6 (2003)
2008 2	Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). [18394162] Crit Care 12(2): R45 (2008)
2007 3	Practical aspects of treatment with drotrecogin alfa (activated). [18269694] Crit Care 11 Suppl 5(-): S7 (2007)
2007 4	The safety profile of drotrecogin alfa (activated). [18269693] Crit Care 11 Suppl 5(-): S6 (2007)
2007 5	Clinical trials in severe sepsis with drotrecogin alfa (activated). [18269692] Crit Care 11 Suppl 5(-): S5 (2007)
2007 6	The protein C pathway: implications for the design of the RESPOND study. [18269691] Crit Care 11 Suppl 5(-): S4 (2007)
2007 7	Recombinant human activated protein C: current insights into its mechanism of action. [18269690] Crit Care 11 Suppl 5(-): S3 (2007)
2007 8	Recombinant activated protein C in sepsis: endothelium protection or endothelium therapy? [17224039] Crit Care 11(1): 103 (2007)
2003 9	Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification. [14624684] Crit Care 7(6): 445-50 (2003)
2007 10	Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. [17592639] BMC Anesthesiol 7(-): 5 (2007)
2006 11	Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. [17319465] Vasc Health Risk Manag 2(1): 3-18 (2006)
2009 12	Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies. [19774207] Biologics 3(-): 391-406 (2009)
2005 13	Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. [15774234] Health Technol Assess 9(11): 1-126, iii-iv (2005)
2009 14	Modulation of sepsis outcome with variants of activated protein C. [19630784] J Thromb Haemost 7 Suppl 1(-): 127-31 (2009)
2007 15	Activated protein C. [17635713] J Thromb Haemost 5 Suppl 1(-): 73-80 (2007)
2004 16	Activated protein C in sepsis. [15099275] J Thromb Haemost 2(5): 708-17 (2004)
2003 17	Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. [12566544] Postgrad Med J 79(927): 5-10 (2003)
2009 18	Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. [19696442] Am J Respir Crit Care Med 180(9): 861-6 (2009)
2007 19	Activated protein C: cost-effective or costly? [17875223] Crit Care 11(5): 164 (2007)
2009 20	Treatment of septic shock and use of drotrecogin alfa (activated) in children. [19735218] Expert Rev Anti Infect Ther 7(7): 769-72 (2009)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Drotrecogin alpha.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Drotrecogin alpha.php on line 92